{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060978","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.700542+00:00","generated_at":"2026-06-14T23:04:56.914866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eloxx Q1 net loss narrows to $6.2M; cash runway into Q3 2023","bullets":["Net loss of $6.2M ($2.88/sh) vs $11.6M ($5.36/sh) in Q1 2022; R&D and G&A expenses decreased.","Cash and equivalents $4.9M at March 31; amended Hercules loan reduced minimum cash to $2.25M, interest-only until Sep 1, 2023.","Current cash expected to fund operations into Q3 2023, assuming Phase 3 activities start in Q3.","Topline data for ELX-02 in Alport syndrome (including biopsy) expected H1 2023; meaningful protein reduction seen in one patient.","FDA cleared ZKN-013 SAD trial for RDEB; preclinical showed up to 18-fold increase in full-length COL VII protein."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060978","json":"https://secwatch.observer/filing/0001104659-23-060978.json","markdown":"https://secwatch.observer/filing/0001104659-23-060978.md","text":"https://secwatch.observer/filing/0001104659-23-060978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/0001104659-23-060978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923060978/tm2315845d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:04:56.914866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}